Engineered Immune Cells Shrink Brain Tumors in Phase 1 Trial
A landmark Phase 1 trial has shown that engineered immune cells, when injected directly into the brain, can shrink glioblastoma tumors. Glioblastoma is the deadliest form of adult brain cancer, and the trial results are being highlighted as a significant advancement in clinical research for the disease.
- The specific treatment uses CAR-T cells, a type of immunotherapy where a patient's own T cells are genetically engineered to fight cancer. This trial, named INCIPIENT, was conducted by researchers at Mass General Cancer Center and involved a novel version of these cells called CARv3-TEAM-E T cells. - Glioblastoma has a very poor prognosis, with a median survival of only 12-18 months with standard treatments like surgery, radiation, and chemotherapy. In the first three patients of this Phase 1 trial, MRIs showed dramatic tumor reduction within days of a single infusion. - The engineered cells were designed with a dual-target approach. They directly attack a cancer-specific mutation (EGFRvIII) while also releasing antibodies to target the common form of the EGFR protein, which is present on over 80% of glioblastoma cells but not on normal brain cells. - While the initial tumor shrinkage was rapid and significant, the effects were temporary, and the tumors later showed signs of progression. The research team's next step is to figure out how to make the response more durable. - This kind of trial involves a direct collaboration between patient-facing and tech-focused life science professionals. Neurosurgeons like Dr. Bryan Choi and oncologists work directly with patients, administering the therapy and monitoring their health. - Patient-facing roles, such as Clinical Research Coordinators, are essential for managing the trial's daily operations. They are responsible for everything from patient recruitment and ensuring study protocols are followed to collecting and documenting the critical data that determines if the therapy is safe and effective. - Behind the scenes, computational biologists and bioinformaticians play a key tech role. They design algorithms and write code to analyze huge datasets from the trial, such as the genetic sequences of the tumors and the activity of the engineered T-cells, to understand why the treatment works and how to improve it.
